Skip To The Main Content


Major players across the healthcare industry—pharmaceutical, biotechnology and life sciences companies, medical device and equipment manufacturers, health insurance companies, hospitals and other providers—turn to Simpson Thacher for deep experience navigating the complexities of the industry. From structuring multibillion dollar mergers and obtaining antitrust approval to advising on disputes and investigations, our healthcare group combines industry-specific experience with unrivaled excellence in the legal disciplines that most affect healthcare companies. Our multidisciplinary team spans the Firm’s best-in-class practices, and includes seasoned transactional, healthcare regulatory and litigation practitioners.

More than $1.2 trillion aggregate value of healthcare deals since 2014
Over 600 corporate representations in healthcare since 2014
“Simpson Thacher couples ‘an impressive level of experience, industry knowledge and business acumen’ with a ‘deep bench.’”
--The Legal 500
Pharma and Biotech
  • PPD’s $17.4 billion acquisition by Thermo Fisher Scientific and its $1.863 billion IPO
  • Valeant (n/k/a Bausch Health Companies) in high-profile securities fraud and RICO class actions; recently secured dismissals in multiple actions
  • CSL in its acquisition of Vifor Pharma and the formation of the CoVIg-19 Plasma Alliance
  • Pfizer’s $1 billion sustainability bond offering, earmarked for COVID-19 vaccine R&D, manufacturing and distribution
  • EQT and Goldman Sachs Asset Management’s $8.5 billion acquisition of Parexel
  • Syneos Health’s debt and equity offerings totaling approximately $3.4 billion
  • 10x Genomics’ $448.5 million IPO, the largest life sciences IPO of 2019
  • Defense of Pfizer in multiple securities litigations
  • Blackstone’s approximately $2.3 billion acquisition of Takeda Consumer Healthcare Company
  • Nuvalent’s $165.75 million initial public offering
  • Patricia Industries and Advanced Instruments in Advanced Instruments’ announced acquisition of Solentim
  • Bayer and Pfizer in false advertising matters
  • Daiichi Sankyo’s high-profile multidistrict “pay-for-delay” antitrust litigation related to Lipitor
Show more
MedTech & Devices
  • Avantors $4.37 billion IPO, the largest healthcare IPO in U.S. history, and multiple debt and equity offerings
  • New Mountain Capital's $2.45 billion acquisition of PerkinElmer’s Applied, Food and Enterprise Services businesses
  • Blackstone, Carlyle and Hellman & Friedman’s majority investment in Medline Industries
  • KKR Biomet in dismissal of all claims in putative securities class action
  • Sotera Health’s $1.2 billion IPO
  • Apria’s $172.5 million IPO, secondary offerings and $1.6 billion acquisition by Owens & Minor
  • Multiple acquisitions and debt offerings for Teleflex
  • Financing for Baxter International’s acquisition of Hillrom
  • Debt offerings for Boston Scientific, AdaptHealth and Agilent Technologies
  • Bioventus’ $120 million initial public offering
  • K2M Group Holdings, Inc.’s acquisition by Stryker Corporation for approximately $1.4 billion
  • medical device company in connection with allegations raised relating to FDA and FCPA compliance issues
  • PHC Holdings’ $1.14 billion acquisition of the Anatomical Pathology business of Thermo Fisher
  • Avantor’s $2.9 billion acquisition of the Masterflex bioprocessing business and related assets of Antylia Scientific
  • Financing for Thermo Fisher’s $11.5 billion acquisition of Qiagen
  • Laborie Medical Technologies’ acquisition of Pelvalon
Show more
Payors and Providers
  • CVS Health’s $40 billion debt offering, the third-largest corporate bond sale on record, to finance its acquisition of Aetna, and multiple other debt offerings
  • Cigna’s debt offerings, totaling more than $10.3 billion
  • 21st Century Oncology in a civil suit alleging monopolization and attempted monopolization in violation of Sherman Act Section 2
  • Bright Health Group’s $924.3 million initial public offering
  • Buyer consortium in going-private transaction of New Frontier Corporation, operator of United Family Healthcare
  • Debt offerings for Community Health Systems, Humana, UnitedHealth Group, Voyage Care and Universal Health Services
  • HCA’s IPO and multiple debt and equity offerings
  • InnovAge’s $350 million IPO
  • Apax’s acquisition of Eating Recovery Center
  • Blackstone Tactical Opportunities’ financing for the acquisition of a majority stake in Deca Dental Group
  • HCA in resolution of a class-action lawsuit alleging that three defendant hospital networks conspired to depress nurse wages 
  • National healthcare provider in a criminal antitrust “no-poach” investigation
  • An insurance carrier concerning a computer data access incident that resulted in investigations by various state and federal government and regulatory entities, including the Department of Health and Human Services and the DOJ
Show more
Healthcare IT & Services
  • WW International's $132 million acquisition of Sequence
  • McKesson's $875 million acquisition of Rx Savings Solutions
  • Microsoft’s $19.7 billion acquisition of Nuance Communications, Inc.
  • McKesson in dismissal of antitrust class action concerning alleged price-fixing conspiracy among manufacturers of generic pharmaceuticals
  • Change Healthcare’s $13.8 billion acquisition by UnitedHealth and its $928 million IPO and concurrent equity offering
  • Waystar's acquisition of HealthPay24
  • MultiPlan’s $11 billion merger with Churchill Capital Corp III
  • Certara’s $768.5 million IPO, $310 million acquisition of Pinnacle 21 and acquisition of Insight Medical Writing
  • Waystar’s $1.35 billion acquisition of eSolutions and acquisition of Patientco
  • Signify Health’s $648.6 million IPO
  • Hellman & Friedman’s minority strategic investment in PointClickCare Technologies
  • EQT’s acquisition of a 20% stake in 3Shape
  • BlackRock Long Term Private Capital’s acquisition of a majority interest in Transaction Data Systems 
  • Weight Watchers in securing a dismissal for a securities class action alleging false and misleading statements regarding its financial performance 
  • EQT Partners’ $2.7 billion acquisition with CPPIB of a majority stake in Waystar
Show more

Why Simpson Thacher for Healthcare?

M&A: Advice across the full spectrum of transactions, including negotiated and unsolicited mergers and takeovers, minority investments and JVs, buyouts and reverse mergers, among others
“Antitrust Litigation Department of the Year” (The American Lawyer)  Shareholder Activism: Advice on governance, corporate, securities, regulatory and litigation issues raised in activist situations
 Financings: Top-tier capital markets and banking practices Intellectual Property: Defense of clients in patent litigations that are unusually risky or complex. Technology platform and analytics database for patents
 Arbitration, Litigation and Investigations: Premier disputes practice, with extensive trial and arbitration experience
 Privacy and Cybersecurity: Understanding of the heightened regulatory, contractual and consumer obligations surrounding the management of data   Named Real Estate Practice Group of the Year by Law360 for nine years, the most recognized law firm in the category. Advice on acquisition or disposition of life science and medical real estate assets  Private Equity: Long-standing role that dates back to our work with the pioneers of the industry. Advice on private equity investments in the healthcare sector and direct work with portfolio companies

    News & Events



        Spotlight on
        Simpson Thacher Named a Law360 Health Care “Practice Group of the Year” for 2023
        Spotlight on
        Simpson Thacher Hosts 2024 Healthcare Perspectives Event
        Spotlight on
        Simpson Thacher Matter Named “Impact Deal of the Year” at 2023 LMG Life Sciences Awards EMEA
        Spotlight on
        Sara Razi Co-Authors CPI Article on FTC’s Approach Surrounding Physician Group Mergers
        Spotlight on
        Bill Brentani Profiled as Law360 Healthcare “MVP”